Glycoprotein IIb/IIIa Receptor Inhibitors: Putting the EPIC, IMPACT II, RESTORE, and EPILOG Trials into Perspective
- 1 August 1996
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 78 (3), 35-40
- https://doi.org/10.1016/s0002-9149(96)00490-0
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular MedicineNew England Journal of Medicine, 1995
- Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapyBMJ, 1994
- Prospects for the use of antagonists to the platelet glycoprotein IIb/ IIIa receptor to prevent postangioplasty restenosis and thrombosisJournal of the American College of Cardiology, 1991
- Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1990
- Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1988
- The platelet membrane glycoprotein IIb-IIIa complexBlood, 1988
- Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty.Circulation, 1987
- Integrins: A family of cell surface receptorsCell, 1987
- Platelet Membrane Glycoprotein IIb/IIIa: Member of a Family of Arg-Gly-Asp—Specific Adhesion ReceptorsScience, 1986
- A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.Journal of Clinical Investigation, 1985